Assessment of the acute safety of cardiac stereotactic ablative radiotherapy for the treatment of ventricular tachycardia

Chris O'Brien Lifehouse0 个研究点目标入组 15 人开始时间: 2023年1月18日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•1. The participant must have documented sustained monomorphic ventricular tachycardia as documented on either a 12-lead ECG or intracardiac ICD interrogation
•b. Monomorphic PVCs documented on a 12-lead ECG.
•2. The patient must have failed or become intolerant to at least one antiarrhythmic medication (amiodarone, sotalol, or mexiletine).
•3. The participant must have failed at least one invasive catheter ablation procedure, or have a contraindication to a catheter ablation procedure (e.g., LV thrombus, severe pulmonary disease), or have VT thought to arise from a protected location (e.g., epicardial VT with history of previous cardiac surgery).
•4. Participant must have either at least 3 VT episodes (sustained VT, ICD ATP or ICD shock) over previous 6 months prior to enrolment
•b. >20% PVC burden with a cardiomyopathy (LVEF<50%)
•5. Participant must be deemed medically fit for stereotactic ablative body radiotherapy by the treating cardiologist and radiation oncologist.
•6. Participant must be over the age of 18 years old.
•7. Participant must have willingness to provide informed consent and a willingness to participate and comply with the study requirements.

•1.Prior radiotherapy within the treatment field
•2.Heart failure dependent on inotropes or left-ventricular assist device
•3.Ventricular fibrillation, >3 distinct clinical VT morphologies or > 5 VT induced VT morphologies during previous electrophysiology studies.
•4.Advanced myocardial scar substrate that would require stereotactic delivery to a target volume deemed unsafe by the treating physician
•5.Patient must not be pregnant and/or breastfeeding and must have a negative pregnancy test within 14 days of study entry.

发起方